Hinova Pharmaceuticals Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Public

  • Employees
  • 241

Employees

  • Stock Symbol
  • 688302

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $4.57
  • (As of Monday Closing)

Hinova Pharmaceuticals General Information

Description

Hinova Pharmaceuticals Inc is an international drug company based on technology platforms such as deuterium and PROTAC, aiming to develop Best-in-class and First-in-class drugs with major clinical needs. The company focuses on the research and development of drugs in therapeutic areas such as oncology and metabolic diseases, focusing on providing safe, effective and affordable drugs for patients, and is committed to the development and production of drugs with global rights and interests.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 4th Floor, Building 1, Rongyao Building
  • No. 5, Keyuan South Road, High-tech Zone
  • Chengdu, Sichuan 610041
  • China
+86 028
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Stock Exchange
SHG
Vertical(s)
Corporate Office
  • 4th Floor, Building 1, Rongyao Building
  • No. 5, Keyuan South Road, High-tech Zone
  • Chengdu, Sichuan 610041
  • China
+86 028

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Hinova Pharmaceuticals Stock Performance

As of 16-Nov-2026, Hinova Pharmaceuticals’s stock price is $4.57. Its current market cap is $452M with 99M shares.

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$4.57 $4.78 $3.97 - $8.49 $452M 99M 2.05M -$0.20

Hinova Pharmaceuticals Financials Summary

As of 30-Sep-2026, Hinova Pharmaceuticals has a trailing 12-month revenue of $12.4M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 391,011 595,509 293,341 561,340
Revenue 12,437 2,846 51 0
EBITDA (20,761) (19,190) (28,291) (42,173)
Net Income (20,113) (19,086) (27,803) (41,578)
Total Assets 183,212 187,195 186,515 210,417
Total Debt 15,483 15,134 1,240 1,813
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Hinova Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Hinova Pharmaceuticals‘s full profile, request access.

Request a free trial

Hinova Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Hinova Pharmaceuticals Inc is an international drug company based on technology platforms such as deuterium and PROTAC,
Drug Discovery
Chengdu, China
241 As of 2025

Shanghai, China
 

Beijing, China
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Hinova Pharmaceuticals Competitors (3)

One of Hinova Pharmaceuticals’s 3 competitors is Haihe Biopharma, a Venture Capital-Backed company based in Shanghai, China.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Haihe Biopharma Venture Capital-Backed Shanghai, China
Mabworks Biotech Venture Capital-Backed Beijing, China
Innovent Biologics Formerly VC-backed Suzhou, China
You’re viewing 3 of 3 competitors. Get the full list »

Hinova Pharmaceuticals Patents

Hinova Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026189052-A1 Small-molecule compound as glp-1 receptor agonist and use thereof Pending 14-Mar-2025
WO-2026145172-A1 Heterocyclic compound, preparation method therefor, and use thereof in preparation of vav1 degradation agent Pending 31-Dec-2024
WO-2026138908-A1 Estrogen receptor degrading agent intermediates and preparation method therefor Pending 24-Dec-2024
WO-2026123850-A1 Salts of androgen receptor degrader, preparation method therefor and use thereof Pending 13-Dec-2024
WO-2026073512-A1 Heterocyclic compound, preparation method therefor, and use thereof for preparing glp-1 receptor agonist prodrug having oral pk characteristics and long-acting pk characteristics Pending 01-Oct-2024
To view Hinova Pharmaceuticals’s complete patent history, request access »

Hinova Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Hinova Pharmaceuticals Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Hinova Pharmaceuticals‘s full profile, request access.

Request a free trial

Hinova Pharmaceuticals Investments (1)

Hinova Pharmaceuticals’s most recent deal was a Early Stage VC with MagicRNA. The deal was made on 29-Dec-2022.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
MagicRNA 29-Dec-2022 Early Stage VC Drug Discovery
To view Hinova Pharmaceuticals’s complete investments history, request access »

Hinova Pharmaceuticals ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Commercial Services

Industry

Rank

Percentile

Business Support Services

Subindustry

Rank

Percentile

To view Hinova Pharmaceuticals’s complete esg history, request access »

Hinova Pharmaceuticals FAQs

  • When was Hinova Pharmaceuticals founded?

    Hinova Pharmaceuticals was founded in 2013.

  • Where is Hinova Pharmaceuticals headquartered?

    Hinova Pharmaceuticals is headquartered in Chengdu, China.

  • What is the size of Hinova Pharmaceuticals?

    Hinova Pharmaceuticals has 241 total employees.

  • What industry is Hinova Pharmaceuticals in?

    Hinova Pharmaceuticals’s primary industry is Drug Discovery.

  • Is Hinova Pharmaceuticals a private or public company?

    Hinova Pharmaceuticals is a Public company.

  • What is Hinova Pharmaceuticals’s stock symbol?

    The ticker symbol for Hinova Pharmaceuticals is 688302.

  • What is the current stock price of Hinova Pharmaceuticals?

    As of 16-Nov-2026 the stock price of Hinova Pharmaceuticals is $4.57.

  • What is the current market cap of Hinova Pharmaceuticals?

    The current market capitalization of Hinova Pharmaceuticals is $452M.

  • What is Hinova Pharmaceuticals’s current revenue?

    The trailing twelve month revenue for Hinova Pharmaceuticals is $12.4M.

  • Who are Hinova Pharmaceuticals’s competitors?

    Haihe Biopharma, Mabworks Biotech, and Innovent Biologics are competitors of Hinova Pharmaceuticals.

  • What is Hinova Pharmaceuticals’s annual earnings per share (EPS)?

    Hinova Pharmaceuticals’s EPS for 12 months was -$0.20.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process